Please complete the CAPTCHA to continue
@almacgroup.com
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Aaron Cranston Ph.D. is listed as Director - Translational Research, Almac Discovery Ltd. --Passionate about helping start-ups/biotechs to develop novel drugs for patients with cancer and life-threatening diseases; making a difference, changing lives. at Queen's University Belfast, based in Belfast Metropolitan Area, United Kingdom, United Kingdom. AeroLeads shows a work email signal at almacgroup.com and a matched LinkedIn profile for Aaron Cranston Ph.D..
Aaron Cranston Ph.D. previously worked as Director - Translational Research at Almac Discovery and Head of Translational Research at Almac Discovery. Aaron Cranston Ph.D. holds B.Sc.(Hons), Ph.D., Genetics from Queen'S University Belfast.
This section adds company-level context without repeating Aaron Cranston Ph.D.'s masked contact details.
AeroLeads found 1 current-domain work email signal for Aaron Cranston Ph.D.. Compare company email patterns before reaching out.
Pre-clinical biologist with over 20 years' experience in oncology, spanning a strong academic career in cancer genetics followed by a productive career in drug discovery and translational science in three successful small biotechs. Most proud of olaparib which continues to make a real difference to patient treatment, survival and quality of life.Specialties: Oncology, ophthalmology, CNS, metabolism, genetics, preclinical models, project management, establishing teams, drug discovery, translational research and asset commercialisation.
Listed skills include Oncology, Drug Discovery, Cancer, In Vivo, and 36 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Delivered high quality preclinical candidate selection activities in a matrix team environment. Clinical positioning and biomarker development. Leading IHC activities for late-stage lead op projects and adopting machine learning and AI approaches for digital pathology and biomarker development. Evaluating new/novel approaches to improve translational.
Providing high quality oncology programmes in areas of unmet need. We are developing these with our partners and collaborators to deliver first-in-class and best-in-class therapies.
Cambridge, Cambs, GB
Delivering highly innovative therapeutics targeting ubiquitin pathways to treat disease.Established MISSION's internal in vivo pharmacology capability from scratch. Delivered in vivo POC efficacy ahead of company milestones securing Series B funding.Led the internal and external preclinical pharmacology functions to progress novel agents into clinical.
A client facing senior scientific project management role. Line management responsibility.Delivered preclinical models with improved predictability and improved quality to biotechs, academic institutions and major Pharma companies.Member of senior management team.
Offering project management (APM qualified) and preclinical scientific guidance for R&D projects.
Responsible for all in-life biology and bioanalytical deliverables for multiple concurrent projects with drug discovery and translational biology aspects. Most notably, led the in vivo pharmacology development of olaparib (Lynparza), a first-in-class PARP inhibitor approved for BRCA mutant advanced ovarian cancer.Legally responsible for all in-house.
Built in-house in vivo pharmacology capability from scratch.Responsible for providing high quality data for five concurrent pre-clinical drug discovery & development projects to tight timelines.Project management of external CRO and academic collaborations.
Cambridge, England, GB
Led MEN2 Cancer Group under auspices of Prof. Sir Bruce Ponder (Cambridge Institute for Medical Research) delivering on a CRC core funded project grant.Delivered biology projects using transgenic technologies to model human thyroid cancers in vivo; included intramural co-operation and forming a significant number of collaborations at leading international.
Philadelphia, Pennsylvania, US
NIH funded scholar exchange fellowship with Dr Richard Fishel.Biology projects modelling HNPCC using transgenic mouse models.Published extensively on mismatch repair, colon cancer and immunology.
Quick answers generated from the profile data available on this page.
Aaron Cranston Ph.D. works for Queen's University Belfast.
Aaron Cranston Ph.D. is listed as Director - Translational Research, Almac Discovery Ltd. --Passionate about helping start-ups/biotechs to develop novel drugs for patients with cancer and life-threatening diseases; making a difference, changing lives. at Queen's University Belfast.
AeroLeads has found 1 work email signal at @almacgroup.com for Aaron Cranston Ph.D. at Queen's University Belfast.
Aaron Cranston Ph.D. is based in Belfast Metropolitan Area, United Kingdom, United Kingdom while working with Queen's University Belfast.
Aaron Cranston Ph.D. has worked for Almac Discovery, Queen'S University Belfast, Mission Therapeutics, Precos Ltd, and Cambridge Preclinical Consulting.
You can use AeroLeads to view verified contact signals for Aaron Cranston Ph.D. at Queen's University Belfast, including work email, phone, and LinkedIn data when available.
Aaron Cranston Ph.D. holds B.Sc.(Hons), Ph.D., Genetics from Queen'S University Belfast.
Aaron Cranston Ph.D. is listed with skills including Oncology, Drug Discovery, Cancer, In Vivo, Pharmaceutical Industry, Life Sciences, Pharmacokinetics, and Pharmacology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts